Latest & greatest articles for aripiprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aripiprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aripiprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aripiprazole

41. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Full Text available with Trip Pro

Aripiprazole versus typical antipsychotic drugs for schizophrenia. Aripiprazole is a relatively new antipsychotic drug, said to be the prototype of a new third generation of antipsychotics; the so-called dopamine-serotonin system stabilisers. In this review we examine how the efficacy and tolerability of aripiprazole differs from that of typical antipsychotics.To evaluate the effects of aripiprazole compared with other typical antipsychotics for people with schizophrenia and schizophrenia-like (...) psychoses.We searched the Cochrane Schizophrenia Group Trials Register (November 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information.We included all randomised trials comparing aripiprazole with typical antipsychotics in people with schizophrenia or schizophrenia-like

2008 Cochrane

42. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study (Abstract)

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study Nonresponse to one or more antidepressants is common and an important public health problem. This study evaluated the efficacy and safety of adjunctive aripiprazole or placebo to standard antidepressant therapy (ADT) in patients with major depressive disorder who showed an inadequate response to at least 1 and up to 3 historical (...) were randomized to adjunctive placebo (n = 190) or adjunctive aripiprazole (n = 191) (starting dose 5 mg/d, dose adjustments 2-20 mg/d, mean end-point dose of 11.0 mg/d). The primary efficacy endpoint was the mean change in Montgomery-Asberg Depression Rating Scale total score from end of prospective treatment phase to end of randomized treatment phase (last observation carried forward). Mean change in Montgomery-Asberg Depression Rating Scale total score was significantly greater with adjunctive

2008 EvidenceUpdates Controlled trial quality: uncertain

43. Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse

Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse Article Text Therapeutics Continuing aripiprazole after stabilisation

2008 Evidence-Based Mental Health

44. Review: aripiprazole for schizophrenia—more high quality research required

Review: aripiprazole for schizophrenia—more high quality research required Review: aripiprazole for schizophrenia—more high quality research required | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: aripiprazole for schizophrenia—more high quality research required Article Text Therapeutics Review: aripiprazole for schizophrenia—more high quality research required Statistics from Altmetric.com Request Permissions If you

2008 Evidence-Based Mental Health

45. Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder

Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder Article Text Therapeutics Adjunctive aripiprazole improves symptoms in antidepressant refractory major

2008 Evidence-Based Mental Health

46. Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone

Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone Article Text Therapeutics Adding aripiprazole improves

2008 Evidence-Based Mental Health

47. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes (...) in patients with schizophrenia Colombo GL, Caruggi M, Di Matteo S, Rossi A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of aripiprazole versus olanzapine for the treatment of patients

2008 NHS Economic Evaluation Database.

48. Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects

Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects Article Text Therapeutics Aripiprazole reduces acute

2007 Evidence-Based Mental Health

49. Abilify (aripiprazole)

Abilify (aripiprazole) 1/29 ?EMEA 2005 SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Abilify. For information on changes after approval please refer to module 8. 1. Introduction Schizophrenia is a major psychotic disorder. Its essential features consist of a mixture of characteristic signs and symptoms that have been present for a significant length of time during a 1-month period (or for a shorter time if successfully treated), with some signs (...) because their safety profile is complex. The in vitro affinity profile of aripiprazole for dopamine and serotonin receptors is similar to the one of so-called atypical antipsychotics. It is postulated that aripiprazole's mechanism of action is novel as it involves a combination of partial agonist action (agonist/antagonism) at dopamine D2 and serotonin 5-HT 1A receptors and antagonism at serotonin 5-HT 2A receptors. 2. Chemical, pharmaceutical and biological aspects Composition Abilify contains

2006 European Medicines Agency - EPARs

50. Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets

Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets Drug Approval Package: Abilify Discmelt (Aripiprazole) NDA #021729 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets Company: Otsuka Pharmaceutical Co., Ltd. Application No.: 021729 Approval Date: 06/07/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 22, 2007 Note: Documents in PDF format require

2006 FDA - Drug Approval Package

51. Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Full Text available with Trip Pro

Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Article Text Therapeutics Aripiprazole is effective for relapse prevention in people with chronic stable

2005 Evidence-Based Mental Health

52. Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Full Text available with Trip Pro

Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Article Text Therapeutics Aripiprazole is effective against the symptoms of schizophrenia

2005 Evidence-Based Mental Health

53. Aripiprazole for schizophrenia. (Abstract)

Aripiprazole for schizophrenia. Treatment of people with schizophrenia using older typical antipsychotic drugs such as haloperidol can be problematic. Many fail to respond and more experience disabling adverse effects. Aripiprazole is said to be one of a new generation of atypical antipsychotics with good antipsychotic properties and minimal adverse effects.To evaluate the effects of aripiprazole for people with schizophrenia and schizophrenia-like psychoses.The reviewers searched the Cochrane (...) Schizophrenia Group's Register (May 2003) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. References of all identified studies were inspected for further trials. The authors contacted relevant pharmaceutical companies, the FDA and authors of trials for additional information.All clinical randomised trials comparing aripiprazole with placebo, typical or atypical antipsychotic drugs for schizophrenia and schizophrenia-like psychoses.We extracted data independently

2004 Cochrane

54. Aripiprazole

Aripiprazole Aripiprazole Aripiprazole Winans E Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Winans E. Aripiprazole. University HealthSystem Consortium (UHC). Drug Monograph. 2003 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug

2003 Health Technology Assessment (HTA) Database.

55. Abilify (Aripiprazole) Tablets

Abilify (Aripiprazole) Tablets Drug Approval Package: Abilify (Aripiprazole) NDA #21-436 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Abilify (Aripiprazole) Tablets Company: Otsuka Pharmaceutical Co., Ltd. Application No.: 21-436 Approval Date: 11/15/2002 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Statistical Review(s) (PDF) (PDF) (PDF) Clinical Pharmacology

2002 FDA - Drug Approval Package